Literature DB >> 10485821

Acute toxicity of an anti-Fas antibody in mice.

C Kakinuma1, K Takagaki, T Yatomi, N Nakamura, S Nagata, A Uemura, Y Shibutani.   

Abstract

By histopathologic examination of various organs in 3 normal strains, C3H/HeN, ICR, and DBA/1J, of mice treated intravenously once with anti-Fas antibody (Jo2), we failed to determine any target organ, except the liver, responsible for the acute lethality induced by the Fas/anti-Fas antibody interaction. However, we could show the presence of Fas-mediated apoptosis in other organs aside from the liver and normal mouse strain differences in susceptibility to anti-Fas antibody. Among these strains, C3H/HeN was the most susceptible to the antibody, followed by ICR and DBA/1J. We observed Fas-mediated apoptosis in the liver, spleen, thymus, lymph nodes, Peyer's patch, intestine, skin, coagulation glands, ovary, uterus, and vagina in all 3 strains and additionally in the epididymides and seminal vesicles in the DBA/1J strain. We also demonstrated that Fas-mediated apoptosis of small lymphocytes in the mantle zone of splenic lymphatic follicles preceded that of the hepatocytes or thymic cells. Since cellular damage was most severe in the liver among all the apoptotic organs in the 3 mouse strains, liver injury induced by anti-Fas antibody is speculated to play a significant role in the death.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10485821     DOI: 10.1177/019262339902700404

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  9 in total

Review 1.  Rationale for Adjunctive Therapies for Pediatric Sepsis Induced Multiple Organ Failure.

Authors:  Bradley S Podd; Dennis W Simon; Santiago Lopez; Andrew Nowalk; Rajesh Aneja; Joseph A Carcillo
Journal:  Pediatr Clin North Am       Date:  2017-08-18       Impact factor: 3.278

2.  Cytosolic phospholipase A(2)α protects against Fas- but not LPS-induced liver injury.

Authors:  Guiying Li; Weina Chen; Chang Han; Tong Wu
Journal:  J Hepatol       Date:  2011-04-14       Impact factor: 25.083

3.  Fas-disabling small exocyclic peptide mimetics limit apoptosis by an unexpected mechanism.

Authors:  Akihiro Hasegawa; Xin Cheng; Kiichi Kajino; Alan Berezov; Kaoru Murata; Toshinori Nakayama; Hideo Yagita; Ramachandran Murali; Mark I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-14       Impact factor: 11.205

Review 4.  Impact of asialoglycoprotein receptor deficiency on the development of liver injury.

Authors:  Serene M L Lee; Carol A Casey; Benita L McVicker
Journal:  World J Gastroenterol       Date:  2009-03-14       Impact factor: 5.742

5.  Fas-induced apoptosis increases hepatocyte tissue factor procoagulant activity in vitro and in vivo.

Authors:  Michelle Lopez; Anna K Kopec; Nikita Joshi; Julia E Geddings; Holly Cline; Keara L Towery; Cheryl E Rockwell; Nigel Mackman; James P Luyendyk
Journal:  Toxicol Sci       Date:  2014-07-11       Impact factor: 4.849

6.  Elevation of serum fortilin levels is specific for apoptosis and signifies cell death in vivo.

Authors:  Patuma Sinthujaroen; Nattaporn Wanachottrakul; Decha Pinkaew; John R Petersen; Amornrat Phongdara; Melinda Sheffield-Moore; Ken Fujise
Journal:  BBA Clin       Date:  2014-12-01

Review 7.  Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases.

Authors:  Vesna Risso; Elodie Lafont; Matthieu Le Gallo
Journal:  Cell Death Dis       Date:  2022-03-17       Impact factor: 9.685

8.  The nude mouse as model for liver deficiency study and treatment and xenotransplantation.

Authors:  Isabelle Vidal; Lysiane Richert
Journal:  Int J Hepatol       Date:  2012-10-31

9.  Prostaglandin F2alpha- and FAS-activating antibody-induced regression of the corpus luteum involves caspase-8 and is defective in caspase-3 deficient mice.

Authors:  Silvia F Carambula; James K Pru; Maureen P Lynch; Tiina Matikainen; Paulo Bayard D Gonçalves; Richard A Flavell; Jonathan L Tilly; Bo R Rueda
Journal:  Reprod Biol Endocrinol       Date:  2003-02-11       Impact factor: 5.211

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.